TrialLeukemia2021

Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.

Francois Guilhot et al.PubMed ↗Publisher ↗

No numbers read from the abstract.